Collegium (NASDAQ: COLL) director exercises options, sells 8,700 shares at $37

Rhea-AI Filing Summary

Collegium Pharmaceutical director Garen G. Bohlin exercised stock options and sold the resulting shares in a same-day transaction. On May 11, 2026, Bohlin exercised options for 8,700 shares of common stock at $16.49 per share, then completed an open-market sale of 8,700 shares at a weighted average price of $37.1829 per share. The sale price reflects multiple trades between $37.18 and $37.43. After these transactions, Bohlin directly holds 62,259 shares of Collegium Pharmaceutical common stock, with the exercised option position reduced to zero.

Insider Trade Summary

Net Seller: 8,700 shares ($323,491)

Net Sell 3 txns

Insider BOHLIN GAREN G

Role null

Sold 8,700 shs ($323K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Purchase)	8,700	$0.00	--
Exercise	Common Stock	8,700	$16.49	$143K
Sale	Common Stock	8,700	$37.1829	$323K

Holdings After Transaction: Stock Option (Right to Purchase) — 0 shares (Direct, null); Common Stock — 70,959 shares (Direct, null)

Footnotes (1)

1. The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.18 to $37.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The option is fully vested and exercisable.

Key Figures

Shares sold: 8,700 shares Weighted average sale price: $37.1829 per share Option exercise price: $16.49 per share +3 more

6 metrics

Shares sold 8,700 shares Open-market sale of common stock on May 11, 2026

Weighted average sale price $37.1829 per share Multiple transactions between $37.18 and $37.43

Option exercise price $16.49 per share Exercise of stock option covering 8,700 shares

Shares held after transactions 62,259 shares Direct common stock ownership after exercise and sale

Shares exercised from option 8,700 shares Stock Option (Right to Purchase) converted into common stock

Option expiration date June 9, 2026 Expiration for the exercised stock option grant

Key Terms

open-market sale, derivative exercise/conversion, Stock Option (Right to Purchase), weighted average price, +1 more

5 terms

open-market sale financial

"transaction_action: "open-market sale" for 8,700 common shares"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

derivative exercise/conversion financial

"transaction_action: "derivative exercise/conversion" for option and common stock"

Stock Option (Right to Purchase) financial

"security_title: "Stock Option (Right to Purchase)" with 8,700 underlying shares"

weighted average price financial

"The price reported in column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

fully vested and exercisable financial

"The option is fully vested and exercisable."

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BOHLIN GAREN G

(Last) (First) (Middle)

C/O COLLEGIUM PHARMACEUTICAL, INC.

100 TECHNOLOGY CENTER DRIVE

(Street)

STOUGHTON MASSACHUSETTS 02072

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
COLLEGIUM PHARMACEUTICAL, INC [ COLL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/11/2026		M		8,700	A	$16.49	70,959	D
Common Stock	05/11/2026		S		8,700	D	$37.1829(1)	62,259	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Purchase)	$16.49	05/11/2026		M			8,700	(2)	06/09/2026	Common Stock	8,700	$0	0	D

Explanation of Responses:

1. The price reported in column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $37.18 to $37.43, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

2. The option is fully vested and exercisable.

	/s/ Colleen Tupper as Attorney-in-Fact for Garen G. Bohlin	05/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did COLLEGIUM PHARMACEUTICAL (COLL) report for Garen G. Bohlin?

Collegium Pharmaceutical reported that director Garen G. Bohlin exercised options for 8,700 common shares at $16.49 and sold 8,700 shares in the open market. These transactions occurred on May 11, 2026 as a combined exercise-and-sell event.

How many COLLEGIUM PHARMACEUTICAL (COLL) shares did Garen G. Bohlin sell and at what price?

Garen G. Bohlin sold 8,700 shares of Collegium Pharmaceutical common stock in open-market trades at a weighted average price of $37.1829 per share. Individual trades occurred within a reported price range from $37.18 to $37.43, inclusive.

What stock options did Garen G. Bohlin exercise in the latest COLLEGIUM PHARMACEUTICAL (COLL) Form 4?

Bohlin exercised a fully vested stock option covering 8,700 shares of Collegium Pharmaceutical common stock at a $16.49 exercise price. Following this exercise, the option position reported in the filing shows zero remaining derivative shares outstanding from that particular grant.

How many COLLEGIUM PHARMACEUTICAL (COLL) shares does Garen G. Bohlin own after the Form 4 transactions?

After the May 11, 2026 exercise and sale, Garen G. Bohlin directly holds 62,259 shares of Collegium Pharmaceutical common stock. This figure reflects his position after both the 8,700-share option exercise and the corresponding 8,700-share open-market sale.

Was the price range for Garen G. Bohlin’s COLLEGIUM PHARMACEUTICAL (COLL) share sale disclosed?

Yes. The filing states the reported sale price is a weighted average, with shares sold in multiple transactions between $37.18 and $37.43 per share. Bohlin has undertaken to provide full trade details upon request to interested parties.